LakeShore Biopharma Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 3/6
LakeShore Biopharma has a total shareholder equity of CN¥585.2M and total debt of CN¥417.5M, which brings its debt-to-equity ratio to 71.3%. Its total assets and total liabilities are CN¥1.5B and CN¥927.8M respectively.
Anahtar bilgiler
71.3%
Borç/özkaynak oranı
CN¥417.52m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | CN¥246.35m |
| Eşitlik | CN¥585.21m |
| Toplam yükümlülükler | CN¥927.82m |
| Toplam varlıklar | CN¥1.51b |
Son finansal sağlık güncellemeleri
Recent updates
Investors Don't See Light At End Of LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Tunnel And Push Stock Down 66%
Nov 01
LakeShore Biopharma Co., Ltd (NASDAQ:LSB) Looks Inexpensive After Falling 36% But Perhaps Not Attractive Enough
Jun 25Little Excitement Around YS Biopharma Co., Ltd.'s (NASDAQ:YS) Revenues
May 08Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: LSB's short term assets (CN¥903.2M) exceed its short term liabilities (CN¥802.2M).
Uzun Vadeli Yükümlülükler: LSB's short term assets (CN¥903.2M) exceed its long term liabilities (CN¥125.6M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: LSB's net debt to equity ratio (29.3%) is considered satisfactory.
Borcun Azaltılması: Insufficient data to determine if LSB's debt to equity ratio has reduced over the past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: LSB has less than a year of cash runway based on its current free cash flow.
Tahmini Nakit Akışı: LSB has less than a year of cash runway if free cash flow continues to grow at historical rates of 9.1% each year.